Sanofi, Regeneron Announce Positive Results in Praluent Diabetes Study

Jun 11, 2017

Sanofi and Regeneron Pharmaceuticals announced positive results from two Phase 3b/4 trials in patients with diabetes, finding that Praluent significantly reduced low-density lipoprotein cholesterol (LDL).

In the first study -- Odyssey DM-Insulin -- Praluent reduced LDL cholesterol by 48.2% compared with placebo in insulin-treated Type 2 diabetes patients with high cardiovascular risk and high levels of bad cholesterol not controlled by maximum tolerated doses (MTD) of statins.

The second study -- ODYSSEY DM-DYSLIPIDEMIA -- found that Praluent was superior to usual care in lowering non-HDL cholesterol.

The results were unveiled as part of the official symposium of the 77th Scientific Sessions of the American Diabetes Association in San Diego, CA

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments